NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

LXRX

Lexicon Pharmaceuticals Inc

May 23 • 04:00PM ET

0.6599

Dollar change -0.0001
Percentage change -0.02	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB REGN BMRN INCY ALNY IONS NBIX KNSA ALLO

| Held by: VTI VXF IWM SCHA IWN VTWO VHT BBP IWO IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.51	Insider Own	51.24%	Shs Outstand	363.18M	Perf Week	23.30%
Market Cap	239.66M	Forward P/E	-	EPS next Y	-0.31	Insider Trans	0.00%	Shs Float	177.07M	Perf Month	-6.18%
Income	-177.30M	PEG	-	EPS next Q	-0.07	Inst Own	26.54%	Short Float	21.05%	Perf Quarter	-6.02%
Sales	31.21M	P/S	7.68	EPS this Y	49.60%	Inst Trans	-40.30%	Short Ratio	2.43	Perf Half Y	-25.09%
Book/sh	0.34	P/B	1.95	EPS next Y	2.36%	ROA	-49.60%	Short Interest	37.27M	Perf Year	-62.72%
Cash/sh	0.54	P/C	1.23	EPS next 5Y	30.30%	ROE	-86.09%	52W Range	0.28 - 2.45	Perf YTD	-10.64%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-95.22%	52W High	-73.07%	Beta	1.05
Dividend TTM	-	Quick Ratio	2.22	Sales past 5Y	600.60%	Gross Margin	96.22%	52W Low	132.69%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	2.22	EPS Y/Y TTM	37.24%	Oper. Margin	-540.04%	RSI (14)	56.54	Volatility	3.66% 6.28%
Employees	103	Debt/Eq	0.86	Sales Y/Y TTM	1250.63%	Profit Margin	-568.04%	Recom	2.00	Target Price	2.92
Option/Short	Yes / Yes	LT Debt/Eq	0.51	EPS Q/Q	64.55%	Payout	-	Rel Volume	0.21	Prev Close	0.66
Sales Surprise	-10.65%	EPS Surprise	26.32%	Sales Q/Q	11.68%	Earnings	May 13 AMC	Avg Volume	15.35M	Price	0.66
SMA20	2.28%	SMA50	21.29%	SMA200	-34.43%	Trades		Volume	3,184,288	Change	-0.02%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-05-25	Downgrade	Leerink Partners	Outperform → Market Perform	$2 → $1
Jun-17-24	Initiated	H.C. Wainwright	Buy	$10
Apr-30-24	Initiated	Leerink Partners	Outperform	$5
Mar-07-23	Initiated	Jefferies	Hold	$3
Aug-12-22	Initiated	Piper Sandler	Overweight	$10
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral	$7
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral	$2 → $8
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral	$3 → $4
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy	$3
Jul-29-19	Downgrade	Stifel	Buy → Hold	$10 → $4
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy	$24 → $23
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight	$10
Mar-01-17	Reiterated	Wedbush	Outperform	$33 → $38
Mar-01-17	Reiterated	H.C. Wainwright	Buy	$26 → $27
Oct-07-16	Initiated	H.C. Wainwright	Buy	$26

Show Previous Ratings

May-21-25 11:19AM	Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential (Insider Monkey) +7.65%
May-19-25 08:00AM	SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology (GlobeNewswire)
May-15-25 10:00AM	ETFs to Capitalize on the Novo Nordisk-Septerna Deal (Zacks)
May-14-25 09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna (Yahoo Finance) -15.57%
09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna (Yahoo Finance)
03:18AM	Loading…
03:18AM	Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com)
May-13-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -6.51%
04:06PM	Lexicon: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
May-12-25 08:50AM	Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 07:00PM	Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 04:30PM	Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) -8.90%
08:00AM	Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire)
Apr-29-25 02:29PM	Growth Is Priced Out Of Novo Nordisk (Seeking Alpha)
Apr-02-25 10:18AM	LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? (Zacks) +8.40%
08:00AM	Loading…
08:00AM	Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-28-25 06:10PM	Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) (Seeking Alpha) +64.13% -19.23%
04:17PM	Novo Nordisk Inks Its Second Big Obesity Deal In A Week And It's Not For A GLP-1 (Investor's Business Daily)
01:04PM	Novo Nordisk strikes $1bn deal for Lexicons oral obesity drug (Pharmaceutical Technology)
07:30AM	Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 (GlobeNewswire)
Mar-07-25 08:30AM	Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 (GlobeNewswire) +6.55%
02:17AM	Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-06-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +9.43%
04:18PM	Lexicon: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-04-25 04:15PM	Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (GlobeNewswire) +11.00%
Mar-03-25 07:00AM	Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain (GlobeNewswire) -58.17%
Mar-02-25 04:13PM	Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain (GlobeNewswire)
Feb-18-25 08:00AM	Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) (GlobeNewswire)
Jan-21-25 08:00AM	Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain (GlobeNewswire) +14.25%
09:16AM	Loading…
Jan-06-25 09:16AM	Heres Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey) +15.94%
Jan-02-25 08:00AM	Lexicon Appoints Scott Coiante as Chief Financial Officer (GlobeNewswire) +5.23%
Dec-20-24 04:30PM	Lexicon Announces Receipt of Complete Response Letter for Zynquista (sotagliflozin) (GlobeNewswire) +15.71%
Nov-27-24 07:30AM	Lexicon completes subject enrolment for DPNP trial of LX9211 (Clinical Trials Arena)
Nov-26-24 08:00AM	Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Nov-25-24 04:15PM	Lexicon Pharmaceuticals to Participate in December Investor Conferences (GlobeNewswire) -5.81%
Nov-22-24 07:32AM	Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA (GlobeNewswire) +11.88%
05:05AM	Lexicon to disband sales team, lay off 60% of staff (BioPharma Dive)
Nov-20-24 04:05PM	Lexicon Appoints Ivan H. Cheung to Board of Directors (GlobeNewswire) -8.34%
Nov-14-24 08:00AM	Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago (GlobeNewswire)
Nov-13-24 02:20AM	Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... (GuruFocus.com) -8.40%
Nov-12-24 05:25PM	Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -6.30%
04:25PM	Lexicon: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 07:15AM	Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-07-24 05:02PM	S&P 500 Gains and Losses Today: Index Ticks Higher as Fed Trims Benchmark Rate (Investopedia) +7.44%
Nov-06-24 08:00AM	Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference (GlobeNewswire)
02:58AM	A diabetes drug, twice rejected, stumbles again but its developer persists (Pharma Voice)
Nov-05-24 04:05PM	Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease (GlobeNewswire)
08:00AM	Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024 (GlobeNewswire)
Nov-04-24 08:00AM	Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss (GlobeNewswire)
Oct-31-24 06:54PM	Lexicon Announces Outcome of FDA Advisory Committee for Zynquista (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease (GlobeNewswire)
Oct-27-24 05:35PM	FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting (TipRanks)
Oct-23-24 09:00AM	New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024 (GlobeNewswire)
Oct-22-24 08:00AM	Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Oct-17-24 07:15AM	Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe (BioPharma Dive) +5.24%
05:55AM	Lexicon partners Viatris for global expansion of sotagliflozin (Pharmaceutical Technology)
Oct-16-24 04:35PM	Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe (GlobeNewswire) +6.70%
04:34PM	Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe (PR Newswire)
Oct-09-24 03:53PM	Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ... (GuruFocus.com)
Sep-27-24 08:00AM	Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress (GlobeNewswire)
Sep-16-24 08:00AM	Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer (GlobeNewswire)
Sep-10-24 08:00AM	New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes (GlobeNewswire)
Sep-03-24 04:00PM	Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences (GlobeNewswire) -6.94%
08:00AM	New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration (GlobeNewswire)
Sep-01-24 10:26PM	Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
Aug-22-24 11:26AM	Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista (Zacks)
10:33AM	Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD (Pharmaceutical Technology)
Aug-21-24 08:00AM	Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista (GlobeNewswire) +13.69%
Aug-14-24 12:33PM	Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up (Zacks) -5.20%
Aug-13-24 08:30AM	Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio (GlobeNewswire) +8.81%
07:00AM	Lilly opens R&D hub; Ovid and Lexicon lay off staff (BioPharma Dive)
Aug-07-24 08:00AM	Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists (GlobeNewswire)
Aug-01-24 05:15PM	Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -10.22% -16.09%
04:12PM	Lexicon: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-25-24 08:00AM	Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024 (GlobeNewswire) +7.37%
Jul-17-24 11:15AM	FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug (Zacks)
Jul-16-24 08:00AM	Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission (GlobeNewswire) +5.19%
Jul-15-24 08:00AM	New Published Data Highlights Potential Cost-Savings of INPEFA (sotagliflozin) for Heart Failure (GlobeNewswire) +7.07%
Jul-08-24 09:15AM	Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director (GlobeNewswire)
Jun-21-24 08:00AM	Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes (GlobeNewswire) +5.71%
Jun-19-24 08:00AM	Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association (GlobeNewswire)
Jun-18-24 08:00AM	Analysis of INPEFA (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology (GlobeNewswire)
Jun-14-24 08:00AM	Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association (GlobeNewswire)
May-30-24 04:45AM	Lexicon selects Medidata to advance Phase IIb non-opioid pain drug trial (Clinical Trials Arena)
May-29-24 07:30AM	Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024 (GlobeNewswire)
May-14-24 08:03AM	Lexicon Pharmaceuticals Says Post Hoc Analysis of Infepa Trial Showed Decreased Heart Failure Risk; Shares Gain Pre-Bell (MT Newswires)
07:00AM	New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction (GlobeNewswire)
May-09-24 07:30AM	Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024 (GlobeNewswire) +6.78%
May-06-24 10:05AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.17%
May-03-24 07:46AM	Q1 2024 Lexicon Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
04:07AM	Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-02-24 08:59PM	LXRX Stock Earnings: Lexicon Pharmaceuticals Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:05PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:03PM	Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ... (GuruFocus.com)
05:00PM	Lexicon: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-24 10:42AM	Lexicon Pharmaceuticals' Chief Executive Lonnel Coats to Retire (MT Newswires)

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Swain Judith L	Director	May 13 '25	Option Exercise	0.00	36,810	0	85,174	May 13 05:52 PM
Sullivan Diane E.	Director	May 13 '25	Option Exercise	0.00	36,810	0	36,810	May 13 05:51 PM
SOBECKI CHRISTOPHER J	Director	May 13 '25	Option Exercise	0.00	36,810	0	203,865	May 13 05:50 PM
BARKER SAM L	Director	May 13 '25	Option Exercise	0.00	36,810	0	124,459	May 13 05:50 PM
Amouyal Philippe	Director	May 13 '25	Option Exercise	0.00	36,810	0	285,174	May 13 05:49 PM
DEBBANE RAYMOND	Director	May 13 '25	Option Exercise	0.00	36,810	0	1,385,689	May 13 05:48 PM
COATS LONNEL	Former Affiliate	Aug 15 '24	Proposed Sale	1.60	300,000	480,000		Aug 15 04:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LXRX

Lexicon Pharmaceuticals Inc

Upgrade your FINVIZ experience